Trial Profile

A Double-Blind, Placebo-Controlled Phase I Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

Status: Recruiting

Phase of Trial: Phase 0

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SOF SKN (Primary)
Indications Cutaneous lupus erythematosus
Focus Adverse reactions; First in man; Proof of concept
Acronyms HERACLES
Sponsors Noxopharm

Most Recent Events

11 Aug 2025 According to a Noxopharm media release,The safety steering committee has determined the second dose level to be safe and tolerable, hence The trial will therefore now proceed to the third cohort of participants, who will receive a higher dose.
11 Aug 2025 According to a Noxopharm media release, the second dose cohort of SOF-SKN™ has been successfully completed in this trial.
20 Jul 2025 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com